Canopy Growth Stock Could Hit New Highs, Says Signal

Short sellers are still piling on, despite CGC's technical recent behavior

by Lillian Currens

Published on Apr 4, 2019 at 2:05 PM

Cannabis concern Canopy Growth Corp (NYSE:CGC) got off to a hot start in 2019, and is now up 61.1% year-to-date. The equity has taken a breather after bounding up the charts earlier this year, with support at the $42 level serving as a recent floor. While the stock is inching lower today, a historically bullish signal just flashed on the charts which could mean even more upside for CGC. 

Specifically, the equity just came within one standard deviation of its 160-day moving average. According to data from Schaeffer's Quantitative Analyst Rocky White, the equity has run into this trendline three other times in the past three years. The equity was higher one week later 67% of the time, averaging a whopping 19.3% gain. From where the stock currently sits at $42.96, a similar move would have it trading atop the $51 level -- home to its mid-October record highs. 

CGC Chart Apr 4

While the majority of analysts have a positive outlook on Canopy, there's still room for upgrades, should the security continue north. Currently, CGC holds five "buy" or better ratings, and three "holds."

Despite the analyst optimism, short sellers are still swarming. Short interest rose 9.5% in the last two reporting periods. The 23.3 million shorted shares now represent a healthy 11.4% of the stock's available float, and would take three days to cover at CGC's average daily pace of trading. A potential short squeeze could add additional tailwinds, if these traders start jumping off the bearish bandwagon. 


a schaeffer's exclusive

5 HOT STOCK PICKS

Heat up your summer trading with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.
3 Drug Stocks Seeing Unusual Options Trading Today
The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
The brokerage firm thinks the retailer can rally another 26%
This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.